Calithera Biosciences, Inc.
COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGY AGENTS
Last updated:
Abstract:
The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
Status:
Application
Type:
Utility
Filling date:
4 Mar 2021
Issue date:
25 Nov 2021